TY - JOUR
T1 - Therapeutic angiogenesis of three-dimensionally cultured adipose-derived stem cells in rat infarcted hearts
AU - Kim, Ji Hyun
AU - Park, In Su
AU - Park, Yongdoo
AU - Jung, Youngmee
AU - Kim, Soo Hyun
AU - Kim, Sang Heon
N1 - Funding Information:
We thank Prof Jongwon Rhee for providing adipose tissue used for isolation of stem cells. This study was supported by a Korea Science and Engineering Foundation (KOSEF) grant funded by the Korea government (MEST) ( 2006-2004339 ).
PY - 2013/5
Y1 - 2013/5
N2 - Background aims: To successfully treat myocardial infarction (MI), blood must be resupplied to the ischemic myocardium by inducing angiogenesis. Many studies report enhanced angiogenesis using stem cells; however, the therapeutic efficacy of cell transplant remains low because transplanted cells may not survive, be retained at the site of transplant, or develop into vascular tissue. In this study, we assessed the therapeutic potential of three-dimensional cell masses (3DCM) composed of human adipose-derived stem cells (hASC) in a rat MI model. Methods: For formation of 3DCM, hASC were cultured on a substrate with immobilized fibroblast growth factor 2. The morphology and phenotypes of 3DCM were analyzed 1 day after culture. The cells (hASC and 3DCM, 5 × 10 5 cells) were injected into ischemic regions after ligation of the left coronary artery (n = 6 in each group). Cell retention ratio, therapeutic efficacy and vascularization were evaluated 4 weeks after transplant. Results: A spheroid-type 3DCM, which included vascular cells (CD34+/CD31 +/KDR+/α-SMA+) with high production of human vascular endothelial growth factor, was obtained. Infarct size and cardiomyocyte apoptosis were reduced in the 3DCM-injected group compared with the hASC-injected group. The retention ratio of hASC was 14-fold higher in the 3DCM-injected group. Many transplanted cells differentiated into endothelial and smooth muscle cells and formed vascular networks incorporated into host vessels. Conclusions: Transplant of 3DCM may be useful for angiogenic cell therapy to treat MI.
AB - Background aims: To successfully treat myocardial infarction (MI), blood must be resupplied to the ischemic myocardium by inducing angiogenesis. Many studies report enhanced angiogenesis using stem cells; however, the therapeutic efficacy of cell transplant remains low because transplanted cells may not survive, be retained at the site of transplant, or develop into vascular tissue. In this study, we assessed the therapeutic potential of three-dimensional cell masses (3DCM) composed of human adipose-derived stem cells (hASC) in a rat MI model. Methods: For formation of 3DCM, hASC were cultured on a substrate with immobilized fibroblast growth factor 2. The morphology and phenotypes of 3DCM were analyzed 1 day after culture. The cells (hASC and 3DCM, 5 × 10 5 cells) were injected into ischemic regions after ligation of the left coronary artery (n = 6 in each group). Cell retention ratio, therapeutic efficacy and vascularization were evaluated 4 weeks after transplant. Results: A spheroid-type 3DCM, which included vascular cells (CD34+/CD31 +/KDR+/α-SMA+) with high production of human vascular endothelial growth factor, was obtained. Infarct size and cardiomyocyte apoptosis were reduced in the 3DCM-injected group compared with the hASC-injected group. The retention ratio of hASC was 14-fold higher in the 3DCM-injected group. Many transplanted cells differentiated into endothelial and smooth muscle cells and formed vascular networks incorporated into host vessels. Conclusions: Transplant of 3DCM may be useful for angiogenic cell therapy to treat MI.
KW - angiogenesis
KW - cell adhesion substrate
KW - differentiation
KW - human adipose-derived stem cells
KW - myocardial infarction
KW - stem cell transplant
KW - three-dimensional cell mass
KW - vascularization
UR - http://www.scopus.com/inward/record.url?scp=84875752891&partnerID=8YFLogxK
U2 - 10.1016/j.jcyt.2012.11.016
DO - 10.1016/j.jcyt.2012.11.016
M3 - Article
C2 - 23352461
AN - SCOPUS:84875752891
SN - 1465-3249
VL - 15
SP - 542
EP - 556
JO - Cytotherapy
JF - Cytotherapy
IS - 5
ER -